Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,138.80
(
-0.49%
)
US TECH 100
26,370.00
(
-0.75%
)
Dow Jones
49,141.93
(
-0.34%
)
Brent Oil
104.14
(
-0.26%
)
Bitcoin
76,527.37
(
0.24%
)
News Focus
News Focus
Post# of 257458
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122898
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 202169

Wednesday, 08/03/2016 4:10:17 PM

Wednesday, August 03, 2016 4:10:17 PM

Post# of 257458
OCRX has enrolled 195 of 230 patients in STOP-HE and expects to complete enrollment in 4Q16:

http://finance.yahoo.com/news/ocera-therapeutics-reports-second-quarter-200500105.html

The 195 number is up from 180 six weeks ago (#msg-123459268) implying an enrollment rate of about 2.5 patients per week. If the enrollment rate stays at this level, it will take until mid-November to hit 230, meeting the 4Q16 guidance above.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today